Ipamorelin vs Tesamorelin

Ipamorelin: Selective growth hormone secretagogue with minimal side effects. Typical dose 100-300 mcg. Tesamorelin: FDA-approved GHRH analog for HIV-associated lipodystrophy with potent GH-releasing activity. Typical dose 1000-2000 mcg. Both fall under the Growth Hormone category.

Stacking Ipamorelin with Tesamorelin is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Ipamorelin is typically dosed: Two to three times daily (SubQ) for GH optimization and anti-aging; Two to three times daily for Combined with CJC-1295 (Mod GRF). Tesamorelin is typically dosed: Once daily (SubQ) for HIV lipodystrophy (FDA approved); Once daily for Body composition / anti-aging (off-label).

Ipamorelin: Not FDA approved for human use. Clinical development discontinued by Novo Nordisk. Tesamorelin: FDA approved. Egrifta (tesamorelin) approved November 2010 for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Egrifta SV (reformulated single-vial) approved 2019.